{"id":"ly3650150","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3650150 is being developed as a next-generation GLP-1 agonist with potential for improved efficacy or dosing convenience compared to existing agents in this class.","oneSentence":"LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:55.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT07006792","phase":"PHASE4","title":"A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-16","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT05372419","phase":"PHASE3","title":"A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-01-12","conditions":"Atopic Dermatitis","enrollment":90},{"nctId":"NCT06921759","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-21","conditions":"Atopic Hand and Foot Dermatitis","enrollment":206},{"nctId":"NCT05369403","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-12-19","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT05559359","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-18","conditions":"Atopic Dermatitis, Eczema","enrollment":367},{"nctId":"NCT05735483","phase":"PHASE3","title":"A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis","status":"ENROLLING_BY_INVITATION","sponsor":"Eli Lilly and Company","startDate":"2023-03-09","conditions":"Atopic Dermatitis, Eczema","enrollment":310},{"nctId":"NCT04392154","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-06-15","conditions":"Atopic Dermatitis","enrollment":1153},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Atopic Dermatitis","enrollment":301},{"nctId":"NCT06243198","phase":"PHASE1","title":"A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-03-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT04840901","phase":"PHASE1","title":"A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-06-02","conditions":"Healthy","enrollment":242},{"nctId":"NCT04626297","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-17","conditions":"Atopic Dermatitis","enrollment":254},{"nctId":"NCT04760314","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-03-10","conditions":"Dermatitis, Atopic, Dermatitis, Eczema","enrollment":286},{"nctId":"NCT04178967","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-10-29","conditions":"Atopic Dermatitis","enrollment":445},{"nctId":"NCT04250350","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-11","conditions":"Atopic Dermatitis","enrollment":206},{"nctId":"NCT04146363","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-09-24","conditions":"Atopic Dermatitis","enrollment":424},{"nctId":"NCT04250337","phase":"PHASE3","title":"Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-03","conditions":"Atopic Dermatitis","enrollment":228},{"nctId":"NCT03443024","phase":"PHASE2","title":"A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-01-30","conditions":"Atopic Dermatitis","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LY3650150","genericName":"LY3650150","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}